Literature DB >> 10667474

Comparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia.

Y J Yang1, S H Lee, S J Hong, B C Chung.   

Abstract

OBJECTIVE: The role of dietary fatty acids (FAs) in benign and malignant prostatic diseases was investigated by comparing the composition value of serum fatty acids in the normal controls, and patients with prostate cancer (PC) and benign prostatic hyperplasia (BPH). Also, to estimate a possible association between PC risk and PUFAs, omega-3, omega-6 and omega-3/omega-6 FA composition ratios were compared among these groups.
METHODS: Serum samples were obtained from 24 BPH and 19 PC patients, and from 21 age-matched normal male subjects. The serum concentration of 21 fatty acids was determined using gas chromatography/mass spectrometry. RESULT: The proportional values of saturated fatty acids (SFAs) groups demonstrated no specific difference between the control subjects and the patients. In the polyunsaturated fatty acids (PUFAs), we found that the omega-3 PUFAs level was significantly decreased in patient with BPH and PC and that the omega-6 PUFAs level was increased in PC only. The ratio of omega-3/omega-6 PUFAs decreased in the following order of normal, BPH, and PC.
CONCLUSION: It was proposed that the changed composition level of PUFAs including omega-3 and omega-6 PUFAs have certain relationship with both prostatic diseases. Therefore, the ratio of omega-3/omega-6 PUFAs also may have an important association with the benign and malignant status of prostatic disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10667474     DOI: 10.1016/s0009-9120(99)00036-3

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  26 in total

1.  Syndecan-1-dependent suppression of PDK1/Akt/bad signaling by docosahexaenoic acid induces apoptosis in prostate cancer.

Authors:  Yunping Hu; Haiguo Sun; Rick T Owens; Zhennan Gu; Jansheng Wu; Yong Q Chen; Joseph T O'Flaherty; Iris J Edwards
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

2.  Prostate tumor growth can be modulated by dietarily targeting the 15-lipoxygenase-1 and cyclooxygenase-2 enzymes.

Authors:  Uddhav P Kelavkar; Justin Hutzley; Kevin McHugh; Kenneth G D Allen; Anil Parwani
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

3.  Conditional expression of human 15-lipoxygenase-1 in mouse prostate induces prostatic intraepithelial neoplasia: the FLiMP mouse model.

Authors:  Uddhav P Kelavkar; Anil V Parwani; Scott B Shappell; W David Martin
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

4.  Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer.

Authors:  Shihua Wang; Jiansheng Wu; Janel Suburu; Zhennan Gu; Jiaozhong Cai; Linara S Axanova; Scott D Cramer; Michael J Thomas; Donna L Perry; Iris J Edwards; Lorelei A Mucci; Jennifer A Sinnott; Massimo F Loda; Guangchao Sui; Isabelle M Berquin; Yong Q Chen
Journal:  Carcinogenesis       Date:  2011-12-08       Impact factor: 4.944

5.  In vivo and in vitro regulation of syndecan 1 in prostate cells by n-3 polyunsaturated fatty acids.

Authors:  Iris J Edwards; Haiguo Sun; Yunping Hu; Isabelle M Berquin; Joseph T O'Flaherty; J Mark Cline; Lawrence L Rudel; Yong Q Chen
Journal:  J Biol Chem       Date:  2008-04-30       Impact factor: 5.157

6.  15-Lipoxygenase-1-mediated metabolism of docosahexaenoic acid is required for syndecan-1 signaling and apoptosis in prostate cancer cells.

Authors:  Yunping Hu; Haiguo Sun; Joseph T O'Flaherty; Iris J Edwards
Journal:  Carcinogenesis       Date:  2012-10-11       Impact factor: 4.944

7.  Lipids and FA analysis of canine prostate tissue.

Authors:  Nadia M Attar-Bashi; Karyn Orzeszko; Ronald F Slocombe; Andrew J Sinclair
Journal:  Lipids       Date:  2003-06       Impact factor: 1.880

8.  Antimutagenicity and antiproliferative studies of lipidic extracts from white shrimp (Litopenaeus vannamei).

Authors:  Griselda Wilson-Sanchez; Carolina Moreno-Félix; Carlos Velazquez; Maribel Plascencia-Jatomea; Anita Acosta; Lorena Machi-Lara; María-Lourdes Aldana-Madrid; Josafat-Marina Ezquerra-Brauer; Ramón Robles-Zepeda; Armando Burgos-Hernandez
Journal:  Mar Drugs       Date:  2010-11-08       Impact factor: 5.118

Review 9.  Emerging targets in lipid-based therapy.

Authors:  Stephanie C Tucker; Kenneth V Honn
Journal:  Biochem Pharmacol       Date:  2012-12-20       Impact factor: 5.858

10.  A reliable biomarker derived from plasmalogens to evaluate malignancy and metastatic capacity of human cancers.

Authors:  Rosina E Smith; Pablo Lespi; María Di Luca; Claudia Bustos; Fernando A Marra; María J T de Alaniz; Carlos A Marra
Journal:  Lipids       Date:  2007-11-29       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.